Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

PHIO Relative to the S&P 500

PHIO Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Phio Pharmaceuticals Corp. (NASD:PHIO) seasonal charts above shows that a Buy Date of December 26 and a Sell Date of March 16 has resulted in a geometric average return of 6.44% above the benchmark rate of the S&P 500 Total Return Index over the past 11 years. This seasonal timeframe has shown positive results compared to the benchmark in 6 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 11 years by an average of 106.44% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company’s pipeline products include PH-762, PH-804, PH-790, and others.

To download PHIO seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: PHIO